Increase in prevalence of eye-related disorders, rise in awareness of eye health, and advancements in technology are the major factors that drive the growth of the vitrectomy devices market.

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the execution of a five-year ...

Pykus Therapeutics, Inc. ("Pykus" or the "Company"), a clinical-stage medical technology company, announced today that it will present an overview of its investigational retinal sealant, PYK-2101, at ...

According to Singh, the Vista 1-Step needle-point vitrector (MicroSurgical Technology) allows anterior segment surgeons to perform limited vitrectomy. Singh previewed study results that ...

Harrow (HROW) announced the execution of a five-year strategic supply and development agreement for Triesence 40 mg/mL, a preservative-free ...

Retinal detachment was irreversible, but with the groundbreaking contributions of medical pioneers like Jules Gonin in the ...

Shares of Harrow Inc. started Tuesday’s trading session increasing in value somewhat after the Nashville-based eyecare ...

At the EnVision Summit 2025 in San Juan, Puerto Rico, Tania Tai, Lucy Shen, and Shivani Kamat all gave insight into ...

The following is a summary of “Cystoid Macular Edema Following Rhegmatogenous Retinal Detachment Repair Surgery: Incidence, Pathogenesis, Risk Factors and Treatment,” published in the February 2025 ...

The effectiveness of laser peripheral iridotomy (LPI) in managing angle closure glaucoma is uncertain, with studies ...